Taliglucerase, Velaglucerasa alfa (Elelyso, VPRIV)

Elelyso (taliglucerase alfa) and VPRIV (velaglucerase alfa) are covered for Type 1 Gaucher disease in patients aged ≥4 years (no off‑label uses meet evidence standards), with approval for 12 months only after documentation of glucocerebrosidase deficiency by enzyme assay or genetic testing. Prescribers must monitor for serious hypersensitivity—including anaphylaxis and reported immune‑mediated skin reactions—and discontinue infusion and treat immediately if anaphylaxis occurs.

"Elelyso ® (taliglucerase alfa) and VPRIV ® (velaglucerase alfa) are indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.